Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tvardi Therapeutics, Inc.CARA · Entity 7579 | Director | June 04, 2024 | June 06, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tvardi Therapeutics, Inc.
Report date June 04, 2024 · Filed June 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 411,007 |
Reported balance
After 2024-06-04 transaction · row 1
1 source rowRow 1 · 2024-06-04 · Grant · Acquired 301,295 · Balance 411,007 F1: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 4, 2025 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.66 · Expires 2034-06-04 | Direct | 390,000 |
Reported balance
After 2024-06-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-06-04 · Grant · Acquired 390,000 · Balance 390,000 F2: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 4, 2025 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 4, 2025 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.
F2: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 4, 2025 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2024 Filed Jun 6, 2024 16:22 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantStock Option (Right to Buy) · Derivative | 390,000 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0001415889-24-015751 · form4-06062024_080626.xml · derivative · entry 2 VOGELBAUM MARTIN · CIK 0001237624 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 390,000 Underlying: Common Stock · 390,000 shares Expires 2034-06-04 F2 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 4, 2025 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 16:22 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 301,295 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015751 · form4-06062024_080626.xml · nonDerivative · entry 1 VOGELBAUM MARTIN · CIK 0001237624 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 411,007 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 4, 2025 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 16:29 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantStock Option (Right to Buy) · Derivative | 89,923 | $0.00 Strike: $3.09 | $0.00 |
DisclosureSEC source: 0001209191-23-034300 · doc4.xml · derivative · entry 2 VOGELBAUM MARTIN · CIK 0001237624 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,923 Underlying: Common Stock · 89,923 shares Expires 2033-06-01 F2 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 1, 2024 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 16:29 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 64,724 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-034300 · doc4.xml · nonDerivative · entry 1 VOGELBAUM MARTIN · CIK 0001237624 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,712 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 1, 2024 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| September 14, 2022 Filed Sep 16, 2022 16:21 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 10,800 | $10.28 | $111,024.00 |
DisclosureSEC source: 0001209191-22-050320 · doc4.xml · nonDerivative · entry 1 VOGELBAUM MARTIN · CIK 0001237624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,988 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.17 to $10.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| June 02, 2022 Filed Jun 6, 2022 17:49 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantStock Option (Right to Buy) · Derivative | 33,993 | $0.00 Strike: $8.42 | $0.00 |
DisclosureSEC source: 0001209191-22-034624 · doc4.xml · derivative · entry 3 VOGELBAUM MARTIN · CIK 0001237624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,993 Underlying: Common Stock · 33,993 shares Expires 2032-06-02 F3 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 2, 2023 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 02, 2022 Filed Jun 6, 2022 17:49 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 11,876 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-034624 · doc4.xml · nonDerivative · entry 2 VOGELBAUM MARTIN · CIK 0001237624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,788 F2 · shares: Represents a one-time grant of 11,876 RSUs. Each RSU represents the contingent right to receive one share of the common stock of the Issuer. The RSUs are fully vested on the date of grant. Read SEC document |
| June 02, 2022 Filed Jun 6, 2022 17:49 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 23,752 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-034624 · doc4.xml · nonDerivative · entry 1 VOGELBAUM MARTIN · CIK 0001237624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,912 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 2, 2023 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 07, 2021 Filed Jun 7, 2021 19:35 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 8,640 | $13.05 | $112,752.00 |
DisclosureSEC source: 0001209191-21-038766 · doc4.xml · nonDerivative · entry 2 VOGELBAUM MARTIN · CIK 0001237624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,160 F2 · shares: Represents the number of shares sold by the Reporting Person to satisfy the Reporting Person's tax obligations resulting from the settlement of vested RSUs on June 3, 2021. The sales were effected pursuant to a "sell-to-cover" arrangement adopted in accordance with Rule 10b5-1 on May 28, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.99 to $13.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 19:35 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantStock Option (Right to Buy) · Derivative | 21,600 | $0.00 Strike: $13.06 | $0.00 |
DisclosureSEC source: 0001209191-21-038766 · doc4.xml · derivative · entry 3 VOGELBAUM MARTIN · CIK 0001237624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,600 Underlying: Common Stock · 21,600 shares Expires 2031-06-03 F4 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 3, 2022 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 19:35 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 14,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-038766 · doc4.xml · nonDerivative · entry 1 VOGELBAUM MARTIN · CIK 0001237624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,800 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 3, 2022 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 17:30 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 6,000 | $16.09 | $96,540.00 |
DisclosureSEC source: 0001209191-20-059476 · doc4.xml · nonDerivative · entry 1 VOGELBAUM MARTIN · CIK 0001237624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,400 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.07 - $16.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 17:49 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantStock Option (Right to Buy) · Derivative | 21,600 | $0.00 Strike: $15.62 | $0.00 |
DisclosureSEC source: 0001209191-20-035071 · doc4.xml · derivative · entry 2 VOGELBAUM MARTIN · CIK 0001237624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,600 Underlying: Common Stock · 21,600 shares Expires 2030-06-04 F2 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 4, 2021 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 17:49 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 14,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-035071 · doc4.xml · nonDerivative · entry 1 VOGELBAUM MARTIN · CIK 0001237624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,400 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 4, 2021 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 18:04 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $20.44 | $0.00 |
DisclosureSEC source: 0001209191-19-035227 · doc4.xml · derivative · entry 3 VOGELBAUM MARTIN · CIK 0001237624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2029-06-04 F3 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 4, 2020 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 18:04 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-035227 · doc4.xml · nonDerivative · entry 1 VOGELBAUM MARTIN · CIK 0001237624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 4, 2020 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 04, 2019 Filed Jul 1, 2019 17:47 UTC Amendment | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-039793 · doc4a.xml · nonDerivative · entry 1 VOGELBAUM MARTIN · CIK 0001237624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 4, 2020 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 16:31 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $16.07 | $0.00 |
DisclosureSEC source: 0001209191-18-036696 · doc4.xml · derivative · entry 1 VOGELBAUM MARTIN · CIK 0001237624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2028-06-06 F1 · derivative.exercise_date: This option was granted to the reporting person pursuant to the issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on June 6, 2019, subject to the reporting person's continued service as a director through such date. Read SEC document |
| June 21, 2017 Filed Jun 23, 2017 18:37 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $19.50 | $0.00 |
DisclosureSEC source: 0001209191-17-041753 · doc4.xml · derivative · entry 1 VOGELBAUM MARTIN · CIK 0001237624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-21 F1 · derivative.exercise_date: This option was granted to the reporting person pursuant to the issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on June 21, 2018, subject to the reporting person's continued service as a director through such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.